← The whole pipeline
Alopecia areata
An autoimmune condition in which the immune system attacks the hair follicle, causing patchy or total loss. It is not pattern baldness and does not respond to the same treatments.
This is where the field has moved fastest. Nothing systemic was approved anywhere before June 2022; there are now several JAK inhibitors, and the live question has shifted to what you offer the people they do not work for.
Available today
- Baricitinib (Olumiant)ApprovedEli LillyHigh
- Deuruxolitinib (Leqselvi)ApprovedSun PharmaceuticalHigh
- Ritlecitinib (Litfulo)ApprovedPfizerHigh
- Upadacitinib (Rinvoq)ApprovedAbbVieHigh
In development
- Coacillium (LH-8)Filed with regulatorLegacy HealthcareHigh
- Ivarmacitinib (ARQ-252)Filed with regulatorUnknownMedium
- JaktinibPhase 3Suzhou Zelgen BiopharmaceuticalsHigh
- AmlitelimabPhase 2SanofiHigh
- ASLAN003Phase 2ASLAN PharmaceuticalsLow
- BNZ-1Phase 2EquilliumMedium
- BrepocitinibPhase 2Priovant TherapeuticsMedium
- DaxdilimabPhase 2AmgenHigh
- Delgocitinib (LEO 124249)Phase 2LEO PharmaHigh
- DeucravacitinibPhase 2Bristol Myers SquibbHigh
- EtrasimodPhase 2PfizerMedium
- RosnilimabPhase 2AnaptysBioHigh
Discontinued
Kept deliberately — the history of failures is as informative as the successes.
This page is generated from the register and updates with it. It does not rank treatments by efficacy or announce launch dates — see how we track.